Associations of serum amyloid A with the overall burden of cerebral small vessel disease and early neurological deterioration in patients with acute ischemic stroke
10.3760/cma.j.issn.1673-4165.2024.08.005
- VernacularTitle:血清淀粉样蛋白A与急性缺血性卒中患者脑小血管病总体负担和早期神经功能恶化的相关性
- Author:
Jufang CHEN
1
;
Shaofa LI
Author Information
1. 百色市人民医院神经内科，百色 533000
- Keywords:
Ischemic stroke;
Serum amyloid A protein;
Cerebral small vessel diseases;
Magnetic resonance imaging;
Disease progression;
Biomarkers
- From:
International Journal of Cerebrovascular Diseases
2024;32(8):591-596
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the associations of serum amyloid A (SAA) with the overall burden of cerebral small vessel disease (CSVD) and early neurological deterioration (END) in patients with acute ischemic stroke (AIS).Methods:Patients with AIS admitted to the Department of Neurology, Baise People's Hospital from August 2021 to August 2023 were included retrospectively. END was defined as an increase of ≥2 in the National Institutes of Health Stroke Scale (NIHSS) score within 72 hours of onset compared to the admission score. The baseline data of patients with different CSVD burden group, as well as END and non-END groups were compared. Multivariate logistic regression analysis was used to determine the independent correlation factors for the overall burden of CSVD and END. Results:A total of 131 patients with AIS were enrolled, including 78 males (59.54%), aged 63.80±7.34 years. Sixteen patients (12.2%) were in the CSVD overall burden 0-point group, 58 (44.3%) in the 1-point group, 29 (22.1%) in the 2-point group, 22 (16.8%) in the 3-point, and 6 (4.6%) in the 4-point group; and 52 (39.7%) experienced END. There were significant differences in age, diabetes, smoking, drinking, NIHSS score at admission, total burden of CSVD, previous stroke or transient ischemic attack history, homocysteine, fasting blood glucose, uric acid and SAA between the END group and the non-END group (all P<0.05). Multivariate logistic regression analysis showed that SAA was an independent risk factor for END (odds ratio 4.703, 95% confidence interval 2.492-8.875; P<0.001). There was a significant difference in SAA among different CSVD burden groups ( P<0.001), and SAA increased with the increase of CSVD burden score. Ordinal multivariate logistic regression analysis showed that SAA was independently correlated with the overall burden of CSVD (odds ratio 4.576, 95% confidence interval 2.542-8.239; P<0.001). Conclusion:SAA is associated with the overall burden of CSVD and END in patients with AIS.
